Fintel reports that on January 28, 2026, Cantor Fitzgerald upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Neutral to Overweight. As of January 14, 2026, the average one-year price target ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Cabaletta Bio (NasdaqGS:CABA) with a Overweight recommendation. As of October 30, 2025, the average one-year price ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th. Cantor ...

Cantor Fitzgerald assumed coverage of Belite Bio (BLTE) with an Overweight rating and $154 price target Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the ...

Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Korro Bio yesterday and set a price target of $21.00. The company’s shares closed yesterday at $11.54.

Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. A ...